What is the translation of " STUDY ENTRY " in Croatian?

• ulasku u ispitivanje
• uključivanju u ispitivanje
• ulaska u ispitivanje
• početku ispitivanja

Examples of using Study entry in English and their translations into Croatian

The age range at study entry was 1-6 months.
Raspon dobi pri ulasku u ispitivanje bio je 1-6 mjeseci.

A KRAS mutation was reported in 57% of patients at study entry.
Mutacija KRAS bila je zabilježena u 57% bolesnika na ulasku u ispitivanje.

For study entry, patients were required to have ALT levels of1.5 X upper limit of normal ULN.
Uvjet za ulazak bolesnika u ispitivanje bila je razina ALT-a  1, 5 puta iznad gornje granice normale GGN.

Patients had a median platelet count of 14 x 109/l at study entry.
Medijan broja trombocita pri uključenju bolesnika u ispitivanje bio je 14 x 109/l.

Of the 32 patients who had a liver biopsy at study entry, 100% had fibrosis and 31% had cirrhosis.
Od 32 bolesnika kojima je učinjena biopsija jetre pri ulasku u ispitivanje, 100% ih je imalo fibrozu, a 31% cirozu.

Difficile from a stool sample collected no more than 7 days before study entry.
Difficile, provedene na uzorku stolice prikupljenom najviše 7 dana prije uključivanja u ispitivanje.

IGF-I levels, which were low at study entry, were restored to within the normal range with somatropin therapy.
Razine IGF-I, koje su bile niske prilikom ulaska u ispitivanje, terapijom vraćene su unutar normalnog raspona.

Each patient had to have at least 90 seizures in the month prior to study entry.
Svaki je bolesnik morao imati najmanje 90 napadaja u mjesecu prije ulaska u ispitivanje.

Baseline ICS use at study entry was recorded, but not required in the study..
Zabilježena je početna primjena inhalacijskog kortikosteroida pri ulasku u ispitivanje, ali nije se zahtijevala tijekom ispitivanja..

Patients had been diagnosed with ITP for approximately 8 years at the time of study entry.
Bolesnici su imali dijagnozu ITP-a oko 8 godina prije uključivanja u ispitivanje.

Detailed clinical status information will be collected at study entry and on an annual basis for at least 15 years.
Detaljne informacije o kliničkom statusu sakupit će se kod uključivanja u ispitivanje i jednom godišnje tijekom najmanje 15 godina.

The average number of gout flares per patient was 10 during the 18 months prior to study entry.
Prosječan broj pogoršanja gihta po bolesniku bio je 10 tijekom 18 mjeseci prije ulaska u ispitivanje.

Of the patients who had been clinically diagnosed with MCI at study entry, 9(19%) converted to clinical AD 36 months later.
Među bolesnicima kojima je na početku ispitivanja klinički dijagnosticiran MCI u njih 9(19%) je nakon 36 mjeseci dijagnosticiran klinički AB.

One hundred and twelve(89.6%) subjects were refractory to their last regimen prior to study entry.
Stotinu i dvanaest(89,6%) ispitanika bilo je refrakterno na posljednji tretman prije ulaska u ispitivanje.

At study entry, 41% of randomized patients had PSA progression only, whereas 59% of patients had radiographic progression.
Pri uključenju u ispitivanje, 41% randomiziranih bolesnika imalo je progresiju bolesti samo po PSA, dok je 59% bolesnika imalo radiološke znakove progresije bolesti.

The median cumulative RAI activity administered prior to study entry was 350 mCi 12.95 GBq.
Medijan kumulativne aktivnosti RAI-ja primijenjenog prije ulaska u ispitivanje iznosio je 350 mCi 12, 95 GBq.

At study entry, patients must have had penile curvature deformity of at least 30 degrees in the stable phase of Peyronie's disease.
Na ulasku u ispitivanje, bolesnici su morali imati deformirajuću zakrivljenost penisa od najmanje 30 stupnjeva u stabilnoj fazi Peyronijeve bolesti.

Efficacy against HPV-16/18 in women with evidence of HPV-16 or HPV-18 infection at study entry.
Djelotvornost protiv HPV-16/18 u žena sa dokazanom HPV-16 ili HPV-18 infekcijom kod ulaska u ispitivanje.

Approximately 45% of patients had measurable soft tissue disease at study entry, and 12% of patients had visceral(lung and/or liver) metastases.
Oko 45% bolesnika u trenutku uključivanja u ispitivanje imalo je mjerljivu bolest mekog tkiva, a 12% bolesnika imalo je visceralne metastaze pluća i/ili jetra.

A majority of patients(67.2%) had not received disease-modifying therapy during the 2 years before study entry.
Većina bolesnika(67,2%) nije primala lijekove koji modificiraju tijek bolesti tijekom 2 godine prije uključivanja u ispitivanje.

The majority of patients(58%) had LDL- cholesterol> 190 mg/dl at study entry, and 24% of patients with LDL-cholesterol> 190 mg/dl were on lipid lowering medicinal products.
Većina bolesnika(58%) imala je LDL kolesterol> 190 mg/dl pri ulasku u ispitivanje, a 24% bolesnika s LDL kolesterolom> 190 mg/dl uzimalo je lijekove za snižavanje razine lipida.

Mean HbA1c increases were less pronounced in patients with normal glycaemia(n=62 overall) at study entry i.e.
Srednja povećanja HbA1c bila su manje izražena u bolesnika s normalnom glikemijom(n=62 ukupno) kod uključenja u ispitivanje tj.

Among patients who had received imatinib 400 mg prior to study entry, MCyR was achieved in 61% of patients in the dasatinib arm and 50% in the imatinib arm.
Među bolesnicima koji su primali imatinib u dozi od 400 mg prije uključenja u ispitivanje, značajni citogenetski odgovor postiglo je 61% bolesnika u skupini na dasatinibu te 50% bolesnika u skupini na imatinibu.

There was no evidence of protection from disease caused by the HPV types for which subjects were HPV DNA positive at study entry.
Nema dokaza za zaštitu od bolesti uzrokovane HPV tipovima na koje su ispitanice bile HPV DNA pozitivne kod ulaska u ispitivanje.

Four of the five patients who required dialysis at study entry were able to discontinue dialysis for the duration of Soliris treatment, and one patient developed a new dialysis requirement.
Četiri od pet bolesnika kojima je bila potrebna dijaliza u vrijeme uključenja u ispitivanje mogli su prekinuti dijalizu za vrijeme liječenja lijekom Soliris, a jednom je bolesniku trebalo liječenje dijalizom.

Overall, 74% of women enrolled were naïve to both HPV-16 and HPV-18(i.e. DNA negative and seronegative at study entry).
Ukupno 74% svih žena uključenih u studiju nije bilo izloženo HPV tipovima 16 i 18(DNA negativne i seronegativne prilikom ulaska u ispitivanje).

All patients received a 2-week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by Week 15.
Svi su bolesnici pri uključivanju u ispitivanje 2 tjedna primali standardiziranu dozu prednizona od 60 mg/dan, nakon čega je uslijedilo obavezno postupno smanjivanje doze, uz potpuni prestanak primjene kortikosteroida do 15. tjedna.

Four percent of patients had a history of brain metastasis, and 36% of patients had a baseline LDH level greater than ULN at study entry.
Četiri posto bolesnika imalo je metastaze u mozgu u anamnezi, a u 36% bolesnika vrijednost LDH na početku ispitivanja bila je iznad GGN-a.

At study entry, patients were treated with PAH medications(most frequently PDE-5 inhibitor[sildenafil] alone[35.9%], bosentan alone[10.9%], and a combination of bosentan, iloprost, and sildenafil in 10.9% of patients) and continued their PAH treatment during the study..
Pri ulasku u studiju, bolesnici su bili liječeni lijekovima za PAH(najčešće inhibitorom PDE- 5[sildenafil] u monoterapiji[35,9%], bosentanom u monoterapiji[10,9%] i kombinacijom bosentana, iloprosta i sildenafila u 10,9% bolesnika) i nastavili su svoje liječenje za PAH tijekom studije.

Imatinib intolerance included patients who discontinued imatinib because of toxicity and were not in major cytogenetic response at time of study entry.
Intolerancija na imatinib obuhvaćala je bolesnike koji su prestali uzimati imatinib zbog toksičnosti te koji nisu postigli veliki citogenetski odgovor u vrijeme ulaska u ispitivanje.